Clinical Trial Update: Study Of SB-683699 Compared To Placebo In Subjects With Relapsing-Remitting Multiple Sclerosis (MS) [Phase 2]

View source ↗

Summary

A Phase 2 trial comparing SB-683699 to placebo in relapsing-remitting multiple sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• SB-683699

Snippet

Sponsor: GlaxoSmithKline | Conditions: Multiple Sclerosis | Phase 2 | Status: COMPLETED